Bruce I. Sachs

Board Director

Director

Vertex Pharmaceuticals INC / MA Vertex Pharmaceuticals Inc / MA

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 1 buy · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (2 ops.)

€3.0M

▼ Sales (0 ops.)

—

Latest filing published 31 Aug 2026 for VERTEX PHARMACEUTICALS INC / MA. Read the official filing

Filing timeline

BuySale

Bruce I. Sachs

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

50%

T+90 mean return

+3.4%

Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.

Signal history

Bruce I. Sachs: trading record in brief

Bruce I. Sachs is a declared insider of Vertex Pharmaceuticals INC / MA (board member), with filings sourced from SEC (Form 4). The record holds 9 filings, for trades running from 2 August 2021 to 27 August 2026.

Every open-market trade on record is a purchase: 2 purchases worth €3.0M, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 6 option exercises.

The newest entry dates from 31 August 2026: a transaction, in Vertex Pharmaceuticals INC / MA. The clock since the last published purchase (7 August 2025) now reads 437 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.